摘要
Abstract
OBJECTIVE:To evaluate the effectiveness and safety of rolapitant combined with 5-HT3 receptor antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting systematically,and to provide evidence-based reference in clinic.METHODS:Retrieved from CJFD,VIP,Wanfang Database,PubMed,EMBase and Cochrane Library,randomized controlled trials (RCTs) about rolapitant+5-HT3 receptor antagonist+ dexamethasone (trial group) vs.placebo combined with 5-HT3 receptor antagonist+dexamethasone (control group) for the prevention of chemotherapy-induced nausea and vomiting.Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation with Cochrane system evaluator manual 5.1.0.RESULTS:A total of 3 literatures were included,involving 4 RCTs and 2 583 patients.The results of Meta-analysis were as follows:complete remission rate [acute stage:RR=1.10,95％ CI (1.02,1.19),P=0.01;delay stage:RR=1.18,95％ CI (1.11,1.25),P＜0.001;overall stage:RR=1.19,95 ％ CI (1.12,1.26),P＜0.001] and the proportion of patients with ftmctional indexes of vomiting living ＞ 108 [RR =1.10,95 ％ CI (1.04,1.16),P ＜ 0.001] in trial group were significantly higher than control group,with statistical significance.There was no statistical significance in the incidence of ADR between 2 groups[RR=1.10,95 ％ CI (0.82,1.47),P=0.52].CONCLUSIONS:Rolapitant combined with 5-HT3 receptor antagonist and dexamethasone can effectively prevent and relieve chemotherapy-induced nausea and vomiting,and improve the quality of life with good safety.关键词
罗拉吡坦/化疗相关性恶心呕吐/系统评价/疗效/安全性Key words
Rolapitant/Chemotherapy-induced nausea and vomiting/Systematic review/Therapeutic efficacy/Safety分类
医药卫生
